SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is experiencing significant volatility, prompting discussions about a potential market correction or even the start of a bear market. Fed Governor Lisa Cook's comments regarding high valuations are being cited as a possible catalyst for the downturn. Community sentiment is mixed, with both bulls and bears actively trading the volatility and debating potential bottom levels and future direction.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Despite strong earnings, NVIDIA is experiencing a sell-off, leading to widespread discussion about potential market manipulation and whether the AI bubble is bursting. Community sentiment is largely negative, with many questioning the high valuations and pointing to potential downside. Some traders are expressing frustration, while others are seizing the opportunity to buy the dip or profit from short positions.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is seeing significant volatility as traders react to a strong earnings report from NVDA and monitor key economic data, including jobs numbers. Community members are actively debating whether recent market movements signal a continuation of the uptrend or a potential bull trap. Discussions also focus on the possibility of future Fed rate cuts and their potential impact on the technology sector.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending downwards, sparking debate about potential support levels and whether this signals the end of the current cycle. Community members are discussing Michael Saylor's position and potential liquidations, while others point to broader market factors and potential manipulation. The conversation includes opinions on Bitcoin's role as a store of value and its impact on the wider market.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending downwards as it amplifies Bitcoin's movements, with concerns rising about debt leverage and potential liquidation. Community discussions revolve around whether the stock is overvalued and how much further it could drop, with some anticipating a significant decline. Broader market commentary suggests potential risks tied to hedge fund activity and overall market valuations which may impact Strategy.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is experiencing volatility, with community discussions focused on recent price dips and the potential impact of upcoming ETFs and the ISO20022 standard. Sentiment is mixed, with some investors expressing frustration while others remain optimistic about long-term potential and are buying the dip. The community is actively debating whether recent market movements signal a buying opportunity or further declines.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending amid a broader tech sector pullback and ahead of Nvidia's earnings report, with some traders expressing concerns about an AI bubble. The community is debating whether the dip presents a buying opportunity or if further declines are expected, while others are highlighting AMD's partnerships and potential for growth in the AI space. Discussions also include potential price targets and the impact of macroeconomic factors on the stock's performance.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending as rising memory prices, driven by AI data-center demand, spark bullish sentiment and debate over whether the stock is overbought. The community is weighing strong growth prospects against potential short-term pullbacks after a significant year-to-date rally. Recent analyst upgrades and reports of supply constraints are also contributing to the increased interest in $MU.

Safe & Green Holdings Corp. is a design and construction services company, which engages in the provision of code engineered cargo shipping containers. It operates through the following segments: Construction, Medical, Development, and Corporate and Support. The Construction Services segment includes the manufacturing of unit SG ECHO and other modules projects. The Medical segment consists of joint venture COVID-19 laboratory operations. The Development segment focuses on real property development. The Corporate and Support segment includes general corporate expenses such as the executive office, corporate finance, accounting, audit, tax, human resources, risk management, information technology, marketing, and legal groups, corporate overhead, and other items not allocated to any of the company's other segments. The company was founded on December 29, 1993 and is headquartered in Miami, FL.

Safe & Green Holdings Corp

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is trending downwards as investors express concerns about the company's performance, linking it to Ethereum's price struggles and broader crypto market volatility. The community is actively discussing potential support levels, the impact of unrealized losses on ETH holdings, and the effectiveness of the company's accumulation strategy. Some investors are questioning the credibility of bullish forecasts and expressing frustration with the stock's recent performance.

statis crypto Watchlist

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update PR...

Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock

Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of...

<ul class="summary-bullets"><li>In heavily pretreated patients with advanced disease having over 20 different types of cancer who had progressed following multiple prior lines of therapy, intratumoral INT230-6 achieved a disease control rate of 75%.</li><li>In patients with metastatic sarcoma receiving only INT230-6, the median overall survival was 21.3 months, the company noted.</li><li>CEO Lewis H. Bender said that the company has initiated randomized controlled studies, including a late-stage study in sarcoma. &nbsp;</li></ul>Shares of Intensity Therapeutics, Inc. (INTS) jumped 282% on Thursday morning after the company announced the publication of positive data from a study of INT230-6 in the treatment of metastatic and refractory cancers.In heavily pretreated patients with advanced disease having over 20 different types of cancer who had progressed following multiple prior lines of therapy, intratumoral INT230-6 achieved a disease control rate of 75% and a median overall survival of 11.9 months in the trial, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.intensitytherapeutics.com/news-events/press-releases/detail/112/intensity-therapeutics-inc-announces-publication-of">said</a>.In patients with metastatic sarcoma receiving only INT230-6, the median overall survival was 21.3 months, the company noted. In a clinical trial, measuring the median overall survival is one way to assess the effectiveness of a new treatment.INT230-6 induced a qualitative decrease in proliferating cancer cells in injected tumors, and pharmacokinetic results showed that greater than 95% of the active cytotoxic agents remained in the injected tumors, Intensity Therapeutics said.Furthermore, 15 of 64 patients in the trial survived for more than 21 months, the company noted.<h2 class="st-heading-2">What Did Company Executives Say?</h2>“Given the drug's mechanism of action and the data reported in this paper from over 20 types of metastatic solid cancers, such as breast, sarcoma, pancreatic, lung, and head and neck, we believe the study results show the potential of INT230-6 to achieve clinical benefit for metastatic patients of multiple cancer types with or without the use of radiation, systemic drugs or immunotherapy.” Lewis H. Bender, CEO, Intensity TherapeuticsThe CEO added that the company has initiated randomized controlled studies, including a late-stage study in sarcoma. This rare cancer originates in the body's connective tissues, such as bone, muscle, fat, and cartilage.INT30-6 consists of two proven, potent anti-cancer agents, cisplatin and vinblastine sulfate, and a diffusion and cell penetration enhancer molecule. In addition to local disease control and direct tumor killing, it causes a release of a bolus of neoantigens specific to the malignancy, leading to immune system engagement and systemic anti-tumor effects.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/INTS">INTS stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.INTS stock is down 42% this year and approximately 67% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/sensei-biotherapeutics-halts-lead-drug-development-explores-sale-or-merger-options/cLGFvQbR3xf">Sensei Biotherapeutics Halts Lead Drug Development, Explores Sale Or Merger Options</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Is Retail Going Gaga Over INTS Stocks Today?

The firm announced positive data from a study of INT230-6 in the treatment of metastatic and refractory cancers, with 15 of 64 patients in the trial surviving for more than 21 months.

Equity

Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal

Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal Intensity...

Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review

Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ('INVINCIBLE-3 Study') Following Periodic Review Drug Monitoring Committee...

Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6

Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6 Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead...

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cance

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the...

Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement

Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct...

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ('INVINCIBLE-3 Study') in a Late-Breaking Session at the 2024...

Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update PR...

Intensity Therapeutics, Inc. operates as biotechnology company, which develops novel immune-based therapeutic products for cancer treatment. Its product, INT230-6, is a formulation consisting of an amphiphilic cell penetration enhancer molecule combined with cisplatin and vinblastine. The company was founded by Lewis H. Bender in 2012 and is headquartered in Shelton, CT.

Current Price	$0.4001
Prev Close	$0.4274
Open	$0.4172
Dividend Yield	0.00%
50-Day Moving Average	$0.3461
Beta	0.00
Avg. Volume	76.14M
PE Ratio	-0.67

52-Week High	$3.18
52-Week Low	$0.1853
Market Capitalization	$25.67M
EPS (Annual)	-$1.17
Price to Book	2.90
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

INTS
INTENSITY THERAPEUTICS, INC.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest INTS News

INTSINTENSITY THERAPEUTICS, INC.